更新于：2024-06-30
Albenatide
艾本那肽
更新于：2024-06-30
概要
基本信息
原研机构- |
在研机构 |
非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
序列信息
Sequence Code 3958
来源: *****
Sequence Code 37437
来源: *****
关联
12
项与 艾本那肽 相关的临床试验Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
评价健康受试者皮下注射CJC-1134-PC注射液分别与二甲双胍、阿托伐他汀、华法林药物-药物相互作用的临床研究
一项多中心、随机、双盲、安慰剂对照III期临床研究以评价在接受二甲双胍单药或二甲双胍联合胰岛素促泌剂治疗后血糖控制不佳的2型糖尿病患者中CJC-1134-PC注射液每周给药1次的有效性和安全性
100 项与 艾本那肽 相关的临床结果
登录后查看更多信息
100 项与 艾本那肽 相关的转化医学
登录后查看更多信息
100 项与 艾本那肽 相关的专利（医药）
登录后查看更多信息
23
项与 艾本那肽 相关的文献（医药）2024-01-01Japanese journal of ophthalmology
Corneal refractive error and astigmatism in patients aged 6 to 18 years with a history of retinopathy of prematurity and birth weight of <1500 g
Article
作者: Noda, Toru ; Yuzurihara, Daisuke ; Ueno, Ritsuko ; Mita, Tetsuko ; Tachikawa, Takako
PURPOSE:
To investigate corneal refractive power (CR) and astigmatism (AS) in 6- to 18-year-old children with a history of retinopathy of prematurity (ROP) and birth weight of <1500 g who either did or did not undergo retinal photocoagulation (PC).
STUDY DESIGN:
Retrospective study.
METHODS:
We examined 143 eyes of 77 children in 2021. The children were divided into three groups for evaluation of CR and AS: those with a birth weight of ≥2500 g (normal birth weight [NBW] group, 13 eyes) as controls, those with spontaneously resolved ROP (sr-ROP group, 27 eyes), and those who underwent PC for treatment of ROP (PC-ROP group, 103 eyes). Swept-source anterior segment optical coherence tomography was used to analyze the cornea.
RESULTS:
The median CR in the NBW, sr-ROP, and PC-ROP groups was 42.2 (41.3, 42.8) diopters (D), 44.5 (43.2, 45.5) D, and 45.2 (43.8, 46.6) D, respectively. The median AS in the NBW, sr-ROP, and PC-ROP groups was 1.2 (1.0, 1.5) D, 1.1 (0.8, 1.6) D, and 2.1 (1.4, 2.7) D. In the PC-ROP group, the with-the-rule astigmatic axis was 97%. In all three groups, a strong positive correlation was found between the mean anterior and posterior CR (NBW: r=0.795, sr-ROP: r=0.842, PC-ROP: r=0.890) and AS (NBW: r=0.883, sr-ROP: r=0.841, PC-ROP: r=0.860).
CONCLUSION:
CR was significantly higher in the sr-ROP (p=0.013) and PC-ROP (p<0.001) groups than in the NBW group. The PC-ROP group had significantly more AS than the sr-ROP group. There was a strong correlation between the anterior and posterior CR and AS.
2023-12-01International journal of biological macromolecules
Antimicrobial and anti-SARS-CoV-2 activities of smart daclatasvir-chitosan/gelatin nanoparticles-in-PLLA nanofibrous medical textiles; in vitro, and in vivo study
Article
作者: Elkashlan, Akram M ; Hamdi, Mohamed ; Hammad, Mohamed A ; Ali, Isra H
This study aims at the development of electrospun polylactic acid nanofibers (PLLA NFs) incorporating smart daclatasvir-loaded chitosan gelatin nanoparticles to be used as medical textiles. First, smart nanoparticles were prepared through ionic gelation and optimized using Design Expert® software where daclatasvir (DAC), chitosan (CS), and gelatin (GL) amounts were selected to be the independent variables. DAC was used owing to its reported Anti-SARS-CoV-2 activity, CS was chosen due to its antimicrobial activity and GL was used owing to its sensitivity to be hydrolyzed upon exposure to Papain-like protease enzyme (PLpro). The optimum DAC-CS/TAN NPs possessed 109 nm size and 94.44 % entrapment efficiency in addition to sustained drug release for 14 days. Furthermore, upon exposure to PLpro, smart DAC-CS/GL NPs released the whole DAC amount within 3 h. Then, DAC-CS/GL NPs were incorporated within PLLA NFs through electrospinning. Swellability was found to increase gradually reflecting the controlled release of DAC from nanofibers within 3 weeks. Cell viability assessments using human fibroblasts showed that the developed nanofibers possess high biocompatibility. An in-vivo animal model for skin irritation was carried out for two weeks where visual inspection and histopathological investigations showed that neither edema nor erythema were observed.
2023-07-01Biomaterials advances
Assessment of antibacterial properties and skin irritation potential of anodized aluminum impregnated with various quaternary ammonium.
Article
作者: Fortier, Louis-Charles ; Auclair-Gilbert, Myriam ; Gascon, Suzanne ; Soucy, Gervais ; Jann, Jessica ; Fradette, Julie ; Drevelle, Olivier ; Faucheux, Nathalie
The importance of the inert environment in the transmission of pathogens has been reassessed in recent years. To reduce cross-contamination, new biocidal materials used in high touch surfaces (e.g., stair railings, door handles) have been developed. However, their impact on skin remains poorly described. The present study aimed to evaluate the antibacterial properties and the risk of skin irritation of two materials based on hard-anodized aluminum (AA) impregnated with quaternary ammonium compound solutions (QAC#1 or QAC#2). The QAC#1 or QAC#2 solutions vary in composition, QAC#2 being free of dioctyl dimethyl ammonium chloride (Dio-DAC) and octyl decyl dimethyl ammonium chloride (ODDAC). Unlike AA used as a control, both AA-QAC#1 and AA-QAC#2 had excellent and rapid antibacterial efficacy, killing 99.9 % of Staphylococcus aureus and Escherichia coli bacteria, in 15 s and 1 min, respectively. The impregnation solutions (QAC#1 and QAC#2) did not show any skin sensitizing effect on transformed human keratinocytes. Nevertheless, these solutions as well as the materials (AA-QAC#1, AA-QAC#2), and the liquid extracts derived from them, induced a very rapid cytotoxicity on L929 murine fibroblasts (>70 % after 1 h of contact) as shown by LDH, MTS and neutral red assays. This cytotoxicity can be explained by the fast QACs release occurring when AA-QAC#1 and AA-QAC#2 were immersed in aqueous medium. To overcome the limitation of assays based on liquid condition, an in vitro skin irritation assay on reconstructed human epidermis (RHE) was developed. The effect of the materials upon their direct contact with the epidermis grown at the liquid-air interface was determined by evaluating tissue viability and quantifying interleukin-1 alpha (IL-1α) which is released in skin during injury or infection. AA-QAC#1 induced a significant decrease in RHE viability, close to OECD and ISO 10993-10 acceptability thresholds and enhanced the pro-inflammatory IL-1α secretion compared with AA-QAC#2. Finally, these results were corroborated by in vivo assays on mice using erythema and edema visual scores, histological observations, and epidermal thickness measurement. AA had no effect on the skin, while a stronger irritation was induced by AA-QAC#1 compared with AA-QAC#2. Hence, these materials were classified as moderate and slight irritants, respectively. In summary, this study revealed that AA-QAC#2 without Dio-DAC and ODDAC could be a great candidate for high touch surface applications, showing an extremely effective and rapid bactericidal activity, without inducing adverse effects for skin tissue.
100 项与 艾本那肽 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 申请上市 | 中国 | 2024-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 73 | (Arm 1 - Weekly CJC-1134-PC) | 壓網範廠獵範鹹願餘製(網艱襯蓋鑰鑰積遞醖窪) = 醖鹹構鏇鹹鹹鏇膚憲艱 鹹積憲糧壓願構範繭構 (製獵觸壓網遞鬱襯簾窪, 鹽餘壓網構網願鬱壓觸 ~ 艱遞簾艱衊遞夢積觸網) 更多 | - | 2017-07-19 | ||
(Arm 2 - Weekly CJC-1134-PC) | 壓網範廠獵範鹹願餘製(網艱襯蓋鑰鑰積遞醖窪) = 壓壓窪遞製窪艱蓋繭築 鹹積憲糧壓願構範繭構 (製獵觸壓網遞鬱襯簾窪, 鹽製憲衊範願構簾壓範 ~ 艱廠顧襯蓋繭膚蓋遞廠) 更多 | ||||||
临床2期 | 122 | (1.5 mg CJC-1134-PC) | 構築壓憲艱憲鑰窪齋艱(醖鹽艱壓憲鏇網獵窪遞) = 夢選憲範觸醖鏇壓積鏇 顧鹽願鏇觸齋憲觸鬱構 (餘壓襯觸選積簾範糧網, 積夢餘齋鏇夢醖鏇壓醖 ~ 獵繭餘製齋艱簾壓範鏇) 更多 | - | 2017-06-02 | ||
(1.5 or 2.0 mg CJC-1134-PC) | 構築壓憲艱憲鑰窪齋艱(醖鹽艱壓憲鏇網獵窪遞) = 膚襯壓醖繭蓋艱衊構簾 顧鹽願鏇觸齋憲觸鬱構 (餘壓襯觸選積簾範糧網, 窪網膚鹹壓淵鹽憲鹹構 ~ 淵顧選顧淵鬱齋範鏇衊) 更多 | ||||||
临床2期 | 90 | (1.5 mg CJC-1134-PC) | 艱築艱鬱淵憲淵衊糧範(鬱簾製鑰衊憲膚膚醖構) = 獵醖廠繭鹹醖窪鏇築艱 觸蓋壓窪夢齋齋獵廠製 (遞艱觸壓遞製鬱壓製獵, 顧齋蓋醖憲範齋鬱觸顧 ~ 衊衊構廠襯遞窪壓範鬱) 更多 | - | 2017-06-02 | ||
(1.5 mg or 2.0 mg CJC-1134-PC) | 艱築艱鬱淵憲淵衊糧範(鬱簾製鑰衊憲膚膚醖構) = 餘憲網製艱選膚衊淵糧 觸蓋壓窪夢齋齋獵廠製 (遞艱觸壓遞製鬱壓製獵, 膚襯鏇淵簾夢膚齋衊膚 ~ 醖鏇糧窪糧膚鬱顧齋選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用